ClinicalTrials.gg
RecruitingNCT07579741JL18008Updated Aug 6, 2026

A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders

A Phase 1/2 interventional study of JL18008 20 μg/kg and Placebo (for 20 μg/kg Group) in HIV Infections, sponsored by Jecho Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Jecho Biopharmaceuticals Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.

Planned enrollment
42nd of 50
30 · median 145
Started
2026
with 2 others
Phase 1/2
2 of 67
1 open now
Registered
63rd of 67
by date
Lead sponsor
2 of 67
Jecho Biopharmaceuticals Co., Ltd.

Among the 67 studies in HIV Infections with a site in China, this one is the 42nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1/2, and was the 63rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in HIV Infections with a site in China, or all of them as a file.
02

Study summary

The Phase Ib clinical trial is an add-on study based on combination antiretroviral therapy (cART). It adopts a multicenter, randomized, double-blind, placebo-controlled, multiple-dose design to evaluate the safety and efficacy of multiple intramuscular injections of JL18008 added to cART in HIV immunological non-responders (INRs).

Based on the Phase Ia clinical data, three dose groups are planned for the Phase Ib trial: 20, 40, and 70 μg/kg of JL18008. Each group is planned to enroll 10 subjects (8 receiving active drug and 2 receiving placebo). All subjects must maintain their original cART regimen unchanged. Subjects in the active treatment groups will receive JL18008 injection in addition to cART, while those in the control group will receive placebo (JL18008 injection buffer) in addition to cART. The dosing regimen is tentatively once weekly (QW) for 4 consecutive weeks, which constitutes one treatment cycle, followed by an observation/follow-up period. The study drug will be administered by intramuscular injection.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV Infections
  • Ib
  • Immunological Non-Responders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 65 years (inclusive), male or female.
  2. (BMI) 18.0 to 32.0 kg/m² (inclusive); body weight ≥50.0 kg for males and ≥45.0 kg for females.
  3. Receiving combination antiretroviral therapy (cART) for at least 48 months, with a stable antiretroviral regimen for at least 3 months prior to enrollment.

    Maintained -1 RNA below 50 copies/mL for at least 36 months (the earliest test date more than 36 months before enrollment), including transient viral blips (single HIV-1 RNA measurement between 50 and 200 copies/mL after excluding laboratory error). At least two HIV-1 RNA results \<50 copies/mL must be available (one may be from screening).

  4. Immunological non-responder criteria: CD4⁺ T cell count ≤350 cells/μL within 1 year before screening. At least three CD4⁺ T cell counts ≤350 cells/μL within 4 years before enrollment, with intervals of ≥3 months between tests (the third may be from screening).
  5. Willing to use effective non-pharmacological with partner from screening until 3 months after study completion, and no plan for sperm/egg donation during this period.
  6. Able to understand and provide written , and willing to comply with all protocol-specified visits and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the study drug or any of its .
  2. Receipt of , immunomodulators, or systemic cytotoxic therapy within 3 months before screening.
  3. Receipt of hormone therapy within 1 month before screening, except for daily doses ≤10 mg prednisone or equivalent.
  4. History of severe disease requiring systemic treatment or hospitalization, or any active autoimmune disease requiring treatment (including multiple sclerosis).
  5. History of systemic infection (viral, bacterial, parasitic, or fungal) requiring systemic treatment and/or hospitalization, or other opportunistic infection, within 30 days before screening.
  6. Active tuberculosis lesion within 30 days before screening.
  7. Blood disorders associated with hypersplenism (e.g., thalassemia, hereditary spherocytosis, Gaucher's disease, autoimmune hemolytic anemia) or history of splenectomy.
  8. Chronic diarrhea.
  9. Severe cardiovascular disease within 6 months before screening, including myocardial infarction, unstable angina, congestive heart failure ( class ≥II), or arrhythmia requiring medication.
  10. Uncontrolled hypertension, defined as resting systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg on at least two repeated measurements on different days despite antihypertensive treatment.
  11. Positive surface antigen (HBsAg), or positive virus antibody (HCV-Ab) with detectable HCV-RNA, or active syphilis.
  12. Any of the following laboratory abnormalities at screening: \<90 g/L; \<1.5×10⁹/L; count \<100×10⁹/L; serum creatinine >1.5× (ULN); >2.5×ULN; aspartate aminotransferase >2.5×ULN; alkaline phosphatase >2.5×ULN; total >1.5×ULN; >1.5; activated partial thromboplastin time >1.5×ULN.
  13. Diagnosis of cancer within the screening period.
  14. Severe neurological or psychiatric disease, or history of seizures.
  15. History of drug abuse within 3 months before screening, or positive urine drug screen (including morphine, methamphetamine, ketamine, MDMA, THC, cocaine), or history of alcohol abuse.
  16. Participation in another clinical trial with receipt of drug within 3 months before screening.
  17. Vaccination within 6 weeks before screening, or plan to receive any vaccination within 1 year after enrollment.
  18. Pregnancy, positive pregnancy test, or breastfeeding.
  19. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    JL18008 20 μg/kg

    Participants receive JL18008 20 μg/kg intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.

    Drug: JL18008 20 μg/kg

  • Placebo comparator
    Placebo (for 20 μg/kg Group)

    Participants receive placebo (JL18008 injection buffer) intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.

    Drug: Placebo (for 20 μg/kg Group)

  • Experimental
    JL18008 40 μg/kg

    Participants receive JL18008 40 μg/kg intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.

    Drug: JL18008 40 μg/kg

  • Placebo comparator
    Placebo (for 40 μg/kg Group)

    Participants receive placebo (JL18008 injection buffer) intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.

    Drug: Placebo (for 40 μg/kg Group)

  • Experimental
    JL18008 70 μg/kg

    Participants receive JL18008 70 μg/kg intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.

    Drug: JL18008 70 μg/kg

  • Placebo comparator
    Placebo (for 70 μg/kg Group)

    Participants receive placebo (JL18008 injection buffer) intramuscularly once weekly for 4 weeks, in addition to their stable cART regimen.

    Drug: Placebo (for 70 μg/kg Group)

Interventions

  • DrugJL18008 20 μg/kg

    Participants receive JL18008 20 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).

  • DrugPlacebo (for 20 μg/kg Group)

    Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).

  • DrugJL18008 40 μg/kg

    Participants receive JL18008 40 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).

  • DrugPlacebo (for 40 μg/kg Group)

    Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).

  • DrugJL18008 70 μg/kg

    Participants receive JL18008 70 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).

  • DrugPlacebo (for 70 μg/kg Group)

    Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by DAIDS v2.1

    The incidence and severity of adverse events (AEs) and serious adverse events (SAEs). Adverse events are graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1. Assessed from first dose up to Week 24.

    Time frame: Up to 24 weeks

  2. Change from Baseline in Vital Signs: Pulse Rate (bpm)

    Change from baseline in pulse rate. Measured in beats per minute (bpm). Assessed at baseline and Weeks 1, 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  3. Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (mmHg)

    Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Both measured in millimeters of mercury (mmHg). Assessed at baseline and Weeks 1, 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  4. Change from Baseline in Hematology Parameters

    Change from baseline in hematology parameters including white blood cell count (10\^9/L), hemoglobin (g/L), platelet count (10\^9/L), neutrophil count (10\^9/L), lymphocyte count (10\^9/L), and red blood cell count (10\^12/L). Assessed at baseline and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  5. Change from Baseline in Serum Chemistry Parameters

    hange from baseline in serum chemistry parameters including alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), creatinine (μmol/L), triglycerides (mmol/L), total cholesterol (mmol/L), glucose (mmol/L), and electrolytes (Na⁺, K⁺, Cl-, Ca²⁺, Mg²⁺, Pi). Assessed at baseline and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  6. Change from Baseline in Coagulation Parameters

    Change from baseline in coagulation parameters including international normalized ratio (INR), activated partial thromboplastin time (APTT, seconds), prothrombin time (PT, seconds), and fibrinogen (g/L). Assessed at baseline and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  7. Change from Baseline in ECG Parameter: QTcF Interval

    Change from baseline in the QT interval corrected for heart rate using Fridericia's formula (QTcF). Measured in milliseconds (ms). Assessed at baseline and Weeks 1, 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Proportion of Participants with CD4⁺ T Cell Count Increase ≥100 cells/μL from Baseline

    Proportion of participants achieving an increase from baseline in CD4⁺ T cell count of at least 100 cells/μL. Assessed at baseline and Weeks 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  2. Proportion of Participants Achieving CD4⁺ T Cell Count ≥500 cells/μL

    Proportion of participants with CD4⁺ T cell count reaching 500 cells/μL or higher. Assessed at Weeks 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  3. Proportion of Participants with Average CD4⁺ T Cell Count Increase ≥100 cells/μL over 12 Weeks

    Proportion of participants with average increase from baseline in CD4⁺ T cell count of at least 100 cells/μL over the first 12 weeks. Assessed from baseline through Week 12.

    Time frame: Baseline through Week 12

  4. Proportion of Participants with Average CD4⁺ T Cell Count ≥500 cells/μL over 12 Weeks

    Proportion of participants with average CD4⁺ T cell count of 500 cells/μL or higher over the first 12 weeks. Assessed from baseline through Week 12.

    Time frame: Baseline through Week 12

  5. Proportion of Participants with Average CD4⁺ T Cell Count Increase ≥100 cells/μL over 24 Weeks

    Proportion of participants with average increase from baseline in CD4⁺ T cell count of at least 100 cells/μL over the 24-week study period. Assessed from baseline through Week 24.

    Time frame: Baseline through Week 24

  6. Proportion of Participants with Average CD4⁺ T Cell Count ≥500 cells/μL over 24 Weeks

    Proportion of participants with average CD4⁺ T cell count of 500 cells/μL or higher over the 24-week study period. Assessed from baseline through Week 24.

    Time frame: Baseline through Week 24

  7. Change from Baseline in CD4/CD8 T Cell Ratio

    Change from baseline in the ratio of CD4⁺ to CD8⁺ T cells. Assessed at baseline and Weeks 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  8. Proportion of Participants with HIV-1 RNA <50 copies/mL

    Proportion of participants maintaining HIV-1 RNA below 50 copies/mL. Assessed at Weeks 4, 8, 12, 16, 20, and 24.

    Time frame: Up to 24 weeks

  9. Number of Participants with Clinical Events

    Number of participants experiencing clinical events including opportunistic infections, malignancies, and non-AIDS complications (e.g., cardiovascular, renal, hepatic events). Assessed from first dose up to Week 24.

    Time frame: Up to 24 weeks

  10. Change from Baseline in Serum Cytokine Levels (IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, IFN-γ)

    Change from baseline in serum levels of cytokines. All measured in pg/mL. Assessed at baseline, Days 1, 2, 3, 5, 8, 15, 22, 23, 24, 26, 29, and Weeks 8, 12, 16, 20, 24.

    Time frame: Up to 24 weeks

  11. Change from Baseline in Lymphocyte Subset Counts (cells/μL)

    Change from baseline in absolute counts of lymphocytes, T cells (CD3⁺), CD8⁺ T cells, B cells (CD19⁺), natural killer cells (CD56⁺), and their subsets including memory, naive, regulatory, and activation markers (CD38⁺, HLA-DR⁺, PD-1⁺). Assessed at baseline, Days 1, 2, 3, 5, 8, 15, 22, 23, 24, 26, 29, and Weeks 8, 12, 16, 20, 24.

    Time frame: Up to 24 weeks

  12. Peak Plasma Concentration (Cmax) - Single Dose

    Maximum observed plasma concentration following the first dose. Derived directly from the concentration-time data. Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  13. Time to Reach Peak Plasma Concentration (Tmax) - Single Dose

    Time to reach maximum observed plasma concentration following the first dose. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  14. Elimination Half-Life (t½) - Single Dose

    Elimination half-life following the first dose. Calculated as ln(2)/λz, where λz is the terminal elimination rate constant. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  15. Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) - Single Dose

    Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration following the first dose. Calculated using the linear trapezoidal rule. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  16. Area Under the Curve from Time 0 to Infinity (AUC0-inf) - Single Dose

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity following the first dose. Calculated as AUC0-last + Clast/λz. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  17. Area Under the Curve from Time 0 to 168 Hours (AUC0-168h) - Single Dose

    Area under the plasma concentration-time curve from time 0 to 168 hours following the first dose. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  18. Apparent Clearance (CL/F) - Single Dose

    Apparent total clearance of the drug from plasma following extravascular administration. Calculated as Dose / AUC0-inf. Measured in L/h. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  19. Apparent Volume of Distribution (Vz/F) - Single Dose

    Apparent volume of distribution during the terminal phase following extravascular administration. Calculated as Dose / (λz \* AUC0-inf). Measured in L. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours post-dose.

    Time frame: Up to 168 hours after first dose

  20. Steady-State Peak Plasma Concentration (Cmax, ss)

    Maximum observed plasma concentration at steady state following the fourth dose (Week 4). Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  21. Steady-State Time to Reach Peak Plasma Concentration (Tmax, ss)

    Time to reach maximum observed plasma concentration at steady state following the fourth dose. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  22. Steady-State Minimum Plasma Concentration (Cmin, ss)

    Minimum observed plasma concentration at steady state following the fourth dose. Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  23. Steady-State Average Plasma Concentration (Cavg, ss)

    Average plasma concentration at steady state over the dosing interval. Calculated as AUC0-tau / τ. Measured in pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  24. Area Under the Curve Over Dosing Interval (AUC0-tau) - Steady State

    Area under the plasma concentration-time curve over the dosing interval (168 hours) at steady state. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  25. Steady-State Area Under the Curve from Time 0 to Infinity (AUC0-inf, ss)

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity at steady state. Measured in h·pg/mL. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  26. Steady-State Apparent Clearance (CLss/F)

    Apparent total clearance at steady state. Calculated as Dose / AUC0-tau. Measured in L/h. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  27. Steady-State Apparent Volume of Distribution (Vss/F)

    Apparent volume of distribution at steady state. Measured in L. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  28. Steady-State Elimination Half-Life (t½, ss)

    Elimination half-life at steady state. Measured in hours (h). Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  29. Degree of Fluctuation (DF) - Steady State

    Degree of fluctuation at steady state. Calculated as (Cmax, ss - Cmin, ss) / Cavg, ss. No units. Assessed at pre-dose and at 1, 2, 4, 8, 12, 24, 48, 96, and 168 hours after the fourth dose.

    Time frame: Up to 168 hours after the fourth dose (Week 4)

  30. Accumulation Ratio for Cmax (RacCmax)

    Accumulation ratio for peak concentration. Calculated as Cmax, ss / Cmax following first dose. No units. Assessed after first dose and after fourth dose (Week 4).

    Time frame: From first dose to steady state (Week 4)

  31. Accumulation Ratio for AUC (RacAUC0-tau)

    Accumulation ratio for area under the curve. Calculated as AUC0-tau, ss / AUC0-tau following first dose. No units. Assessed after first dose and after fourth dose (Week 4).

    Time frame: From first dose to steady state (Week 4)

  32. Number of Participants with Anti-Drug Antibodies (ADA)

    Number and percentage of participants who develop anti-drug antibodies (ADA) against JL18008. For ADA-positive participants, titers and neutralizing antibody (Nab) status will be assessed. Assessed at baseline, Days 8, 15, 22, 29, and Weeks 8, 12, 16, 20, 24.

    Time frame: Up to 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared. The trial data is proprietary and part of a product development program. Data sharing is not planned at this stage of clinical development.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2027, 8 months after the start.

Of 42 phase 1/2 interventional studies under HIV Infections, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 12, 2026
StartActual
May 26, 2026
Primary completionEst.
Feb 12, 2027
CompletionEst.
Sep 28, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07579741
Responsible party
Sponsor
First posted
May 12, 2026
Start date
May 26, 2026
Primary completion
Feb 12, 2027 (estimated)
Completion
Sep 28, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Prof. Taisheng Li
Contact
litsh@263.net
+86-10-69156114

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion